Human TGF-beta 2 Quantikine ELISA Kit
R&D Systems, part of Bio-Techne | Catalog # DB250
Key Product Details
Assay Length
4.5 hours
Sample Type & Volume Required Per Well
Cell Culture Supernates (125 µL), Serum (125 µL), EDTA Plasma (125 µL), Heparin Plasma (125 µL), Citrate Plasma (125 µL)
Sensitivity
7 pg/mL
Assay Range
31.2-2000 pg/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma, Citrate Plasma)
Product Summary for Human TGF-beta 2 Quantikine ELISA Kit
The Quantikine Human TGF-beta 2 Immunoassay is a 4.5 hour solid-phase ELISA designed to measure activated TGF-beta 2 in cell culture supernates, serum, and plasma. The Quantikine Human TGF-beta 2 Immunoassay contains CHO cell-derived recombinant human TGF-beta 2 and antibodies raised against the recombinant protein. The assay has been shown to quantitate the recombinant factor accurately. Results obtained using human TGF-beta 2 showed linear curves that were parallel to the standard curves obtained using the recombinant TGF-beta 2 kit standards. These results indicate that this kit can be used to determine relative mass values for natural human TGF-beta 2.
Product Specifications
Assay Type
Solid Phase Sandwich ELISA
Format
96-well strip plate
Measurement
Quantitative ELISA
Detection Method
Colorimetric - 450nm (TMB)
Conjugate
HRP
Reactivity
Human
Specificity
Natural and recombinant human TGF-beta 2 and natural porcine TGF-beta 2.
Cross-reactivity
< 0.5% cross-reactivity observed with available related molecules. < 50% cross-species reactivity observed with species tested.
Interference
Interference observed with 1 or more available related molecules.
Precision
Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision.
Cell Culture Supernates, Citrate Plasma, EDTA Plasma, Heparin Plasma, Serum
| Intra-Assay Precision | Inter-Assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (pg/mL) | 194 | 509 | 1044 | 196 | 500 | 1015 |
| Standard Deviation | 13.8 | 27.0 | 28.3 | 9.8 | 21.5 | 43.6 |
| CV% | 7.1 | 5.3 | 2.7 | 5.0 | 4.3 | 4.3 |
Recovery for Human TGF-beta 2 Quantikine ELISA Kit
To assess recovery of the assay, samples of various matrices were spiked with three concentrations of TGF-beta 2, activated, and measured in the assay.
| Sample Type | Average % Recovery | Range % |
|---|---|---|
| Cell Culture Media (n=5) | 101 | 89-113 |
| Citrate Plasma (n=5) | 107 | 93-116 |
| EDTA Plasma (n=5) | 101 | 95-111 |
| Heparin Plasma (n=5) | 102 | 89-113 |
| Serum (n=5) | 86 | 73-95 |
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of TGF-beta 2, activated and then serially diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Scientific Data Images for Human TGF-beta 2 Quantikine ELISA Kit
Human TGF-beta 2 ELISA Standard Curve
Detection of Human TGF-beta 2 by ELISA
ELISA for active and total TGF-beta 2 in the media (A, B). At day 22, the concentration of active and total TGF-beta 2 in the media of IL-13 pre-treated NHBE at 1 and 10 ng/ml is significantly higher as compared to untreated NHBE (0 ng/ml of IL-13) media; * p < 0.01. At day 22 and day 28, the concentration of active TGF-beta 2 in the IL-13 pre-treated NHBE at 10 ng/ml is elevated compared to pre-treated NHBE at 1 ng/ml; # p < 0.01. At day 28 active and total TGF-beta 2 in IL-13 pre-treated NHBE at 10 ng/ml is increased compared to untreated NHBE; * p < 0.01. (C, D) At day 25, the NHBE pre-treated with IL-13 at 10 ng/ml, has higher levels of active and total TGF-beta 2 in the media as compared to untreated and pre-treated NHBE at 1 ng/ml co-cultured with NHLF (*, # p < 0.01 compared to 0 and 1 ng/ml IL-13 pre-treated NHBE co-cultured with NHLF, respectively). At day 31, there is no significant difference in the levels of active and total TGF-beta 2 between treatment conditions. NHLF represents levels of active and total TGF-beta 2 in media of fibroblasts in a collagen gel without NHBE co-culture. All experiments were performed using 3 donors, grown in duplicate, with 3–6 wells per condition. Image collected and cropped by CiteAb from the following open publication (https://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-9-27), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human TGF-beta 2 by ELISA
ELISA for active and total TGF-beta 2 in the media (A, B). At day 22, the concentration of active and total TGF-beta 2 in the media of IL-13 pre-treated NHBE at 1 and 10 ng/ml is significantly higher as compared to untreated NHBE (0 ng/ml of IL-13) media; * p < 0.01. At day 22 and day 28, the concentration of active TGF-beta 2 in the IL-13 pre-treated NHBE at 10 ng/ml is elevated compared to pre-treated NHBE at 1 ng/ml; # p < 0.01. At day 28 active and total TGF-beta 2 in IL-13 pre-treated NHBE at 10 ng/ml is increased compared to untreated NHBE; * p < 0.01. (C, D) At day 25, the NHBE pre-treated with IL-13 at 10 ng/ml, has higher levels of active and total TGF-beta 2 in the media as compared to untreated and pre-treated NHBE at 1 ng/ml co-cultured with NHLF (*, # p < 0.01 compared to 0 and 1 ng/ml IL-13 pre-treated NHBE co-cultured with NHLF, respectively). At day 31, there is no significant difference in the levels of active and total TGF-beta 2 between treatment conditions. NHLF represents levels of active and total TGF-beta 2 in media of fibroblasts in a collagen gel without NHBE co-culture. All experiments were performed using 3 donors, grown in duplicate, with 3–6 wells per condition. Image collected and cropped by CiteAb from the following open publication (https://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-9-27), licensed under a CC-BY license. Not internally tested by R&D Systems.
Preparation and Storage
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Background: TGF-beta 2
The signal transducing receptor for TGF-beta 2 is a heterotetrameric complex of two type I
signal-transducing receptors (53 kDa; TGF-beta RI) and two type II ligand-binding receptors
(75-85 kDa; TGF-beta RII) (14-19). The binding of TGF-beta 2 appears to initially involve a type III TGF-beta
receptor, either 300 kDa betaglycan (20) or 180 kDa endoglin (14, 21), which then "hands off"
to TGF-beta RII.
TGF-beta 2 is expressed by a variety of cells, including osteoclasts, thymic epithelium,
keratinocytes, hepatocytes, chief cells of the stomach, satellite cells, skeletal muscle cells,
prostatic epithelium, bronchial epithelium, neurons and astrocytes, fibroblasts and visceral
smooth muscle, and macrophages (14-19). TGF-beta 2 has marked cross-species bioactivity
(e.g., human TGF-beta 2 is active on mouse cells (33), while porcine TGF-beta 2 is active on rabbit
cells (34)). TGF-beta 2 has four fundamental activities: it is a growth inhibitor for most types of
cells; it enhances the deposition of extracellular matrix; it is immunosuppressive, suppressing
APC expression of both IL-12 and CD40L while upregulating IL-10 secretion; and during fetal
development, it is expressed in discrete areas, such as epithelium, myocardium, cartilage and
bone of extremities and in the nervous system, suggesting specific functions (1, 35-37).
Long Name
Transforming Growth Factor beta 2
Alternate Names
TGFB2, TGFbeta 2
Gene Symbol
TGFB2
Additional TGF-beta 2 Products
Product Documents for Human TGF-beta 2 Quantikine ELISA Kit
Product Specific Notices for Human TGF-beta 2 Quantikine ELISA Kit
For research use only
Loading...
Loading...
Loading...
⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.